T9358
Bluelighter
So there was a start with methylphenidate in the pharmaceutical market, ethylphenidate in the RC market, now 2 studies that can be ran across buy doing a web search ''isopropylphenidate''.
In the study it showed that the isopropylphenidate had just as much potency at the DAT as methylphenidate, but less at the NET ( sounds similar to ethylphenidate to me), although the isopropylphenidate appeared to last a decent amount longer than methylphenidate.
So I had a question, if it seems that a more favorable binding profile is coming from an extension what happened to propylphenidate? AND could this turn into just extending that chain longer and longer?
I believe the study is for a new ADD med, with a more easy dosing schedule.
In the study it showed that the isopropylphenidate had just as much potency at the DAT as methylphenidate, but less at the NET ( sounds similar to ethylphenidate to me), although the isopropylphenidate appeared to last a decent amount longer than methylphenidate.
So I had a question, if it seems that a more favorable binding profile is coming from an extension what happened to propylphenidate? AND could this turn into just extending that chain longer and longer?
I believe the study is for a new ADD med, with a more easy dosing schedule.